vTv Therapeutics Inc. (VTVT)

NCM – Real vaqt narxi. Valyuta: USD

32.00

-1.04 (-3.15%)

Bozor ochiq: Aug 12, 2026, 1:13 PM EDT

33.04

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 4:10 PM EDT

06.08.2026

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

vTv Therapeutics Inc. (VTVT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

vTv Therapeutics Inc. (VTVT)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update